UBS Group Portfolio holdings
UBS Group is the Swiss bank holding company behind UBS, which was created in 1998 when Union Bank of Switzerland merged with Swiss Bank Corporation; the holding company was listed in New York in 2014. Its business spans wealth management, investment banking, asset management and banking for individuals and companies. Its asset management arm offers stock, bond, currency, hedge fund, real estate, infrastructure and private equity strategies, which can also be combined in multi-asset portfolios. The group's roots go back to the Bank in Winterthur, founded in 1862, and to Swiss Bank Corporation, started by six private bankers in Basel by 1854. The wealth management arm serves high net worth individuals worldwide, and its US business grew out of Paine Webber, the American brokerage UBS merged with in 2000 and renamed UBS Wealth Management USA in 2003. In 2023 UBS took over Credit Suisse in a rescue deal arranged by the Swiss government and central bank.
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Microsoft
MSFT
|
+$1.15B |
| 2 |
HONA
Honeywell Aerospace
HONA
|
+$611M |
| 3 |
SpaceX
SPCX
|
+$567M |
| 4 |
Apple
AAPL
|
+$511M |
| 5 |
Jabil
JBL
|
+$463M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
ExxonMobil
XOM
|
+$1.49B |
| 2 |
Western Digital
WDC
|
+$1.42B |
| 3 |
Lumentum
LITE
|
+$951M |
| 4 |
Intel
INTC
|
+$785M |
| 5 |
iShares Core S&P 500 ETF
IVV
|
+$749M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Miscellaneous | 41.93% |
| 2 | Technology | 18.6% |
| 3 | Financials | 7.85% |
| 4 | Industrials | 6.96% |
| 5 | Healthcare | 5.8% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | Held Since | |
|---|---|---|---|---|---|---|---|
8501
CALL
Exelon
EXC
$47.2B
| $9.32K | ﹤0.01% |
200
-691,400
| -100% | -$32M |
2021 Q1
21 quarters
|
|
8502
Rithm Acquisition Corp
RAC
$312M
| $9.3K | ﹤0.01% |
889
| – | – |
2025 Q3
3 quarters
|
|
8503
APEX Tech Acquisition Inc Units
TRAD.U
| $9.3K | ﹤0.01% |
+915
| New | +$9.2K |
2026 Q2
0 quarters
|
|
8504
DELISTED
ETRACS 2x Leveraged US Value Factor TR ETN
IWDL
| $9.3K | ﹤0.01% |
169
-1
| -0.6% | -$58 |
2025 Q4
2 quarters
|
|
8505
Imunon
IMNN
$4.95M
| $9.26K | ﹤0.01% |
5,203
+4,628
| +805% | +$11.4K |
2014 Q4
46 quarters
|
|
8506
Neuphoria Therapeutics
NEUP
$14.9M
| $9.25K | ﹤0.01% |
2,117
-199
| -9% | -$960 |
2025 Q3
3 quarters
|
|
8507
Zevia
ZVIA
$92.4M
| $9.21K | ﹤0.01% |
5,652
-6,936
| -55% | -$9.42K |
2021 Q3
19 quarters
|
|
8508
Lipocine
LPCN
$19M
| $9.21K | ﹤0.01% |
3,596
+102
| +3% | +$245 |
2024 Q1
9 quarters
|
|
|
QGRD
8509
Horizon Nasdaq-100 Defined Risk ETF
QGRD
$159M
| $9.2K | ﹤0.01% |
+302
| New | +$8.68K |
2026 Q2
0 quarters
|
|
8510
Fidelity Disruptive Finance ETF
FDFF
$40.7M
| $9.2K | ﹤0.01% |
278
+210
| +309% | +$6.95K |
2026 Q1
1 quarter
|
|
8511
DGA Absolute Return ETF
HF
$20.7M
| $9.19K | ﹤0.01% |
413
+326
| +375% | +$7.11K |
2026 Q1
1 quarter
|
|
8512
First Trust Indxx Aerospace & Defense ETF
MISL
$681M
| $9.15K | ﹤0.01% |
+200
| New | +$9.16K |
2026 Q2
0 quarters
|
|
8513
DELISTED
Innovator Gradient Tactical Rotation Strategy ETF
IGTR
| $9.1K | ﹤0.01% |
268
+137
| +105% | +$4.33K |
2024 Q3
7 quarters
|
|
8514
ProMIS Neurosciences
PMN
$36.3M
| $9.09K | ﹤0.01% |
691
-609
| -47% | -$6.61K |
2025 Q3
3 quarters
|
|
8515
Blue Gold Ltd
BGL
$5.31M
| $9.09K | ﹤0.01% |
32,690
-918
| -3% | -$766 |
2025 Q3
3 quarters
|
|
8516
iShares iBonds Oct 2030 Term TIPS ETF
IBIG
$162M
| $9.09K | ﹤0.01% |
346
+283
| +449% | +$7.46K |
2026 Q1
1 quarter
|
|
8517
Xtrackers International Real Estate ETF
HAUZ
$1.09B
| $9.06K | ﹤0.01% |
404
-140
| -26% | -$3.26K |
2023 Q1
13 quarters
|
|
|
LMNX
8518
DELISTED
Defiance Daily Target 2x Long LMND ETF
LMNX
| $9.04K | ﹤0.01% |
550
-27
| -5% | -$393 |
2026 Q1
1 quarter
|
|
8519
JPMorgan Fundamental Data Science Large Core ETF
LCDS
$16.3M
| $9.02K | ﹤0.01% |
127
-100
| -44% | -$6.93K |
2024 Q3
7 quarters
|
|
8520
VanEck CMCI Commodity Strategy ETF
CMCI
$3.01M
| $9.02K | ﹤0.01% |
327
-250
| -43% | -$7.19K |
2025 Q1
5 quarters
|
|
8521
F/M Opportunistic Income ETF
ZHOG
$44.8M
| $8.98K | ﹤0.01% |
175
-57
| -25% | -$2.93K |
2026 Q1
1 quarter
|
|
8522
Cardiol Therapeutics
CRDL
$125M
| $8.98K | ﹤0.01% |
8,471
-138
| -2% | -$175 |
2021 Q4
18 quarters
|
|
8523
State Street My2034 Corporate Bond ETF
MYCN
$9.45M
| $8.97K | ﹤0.01% |
+366
| New | +$8.97K |
2026 Q2
0 quarters
|
|
8524
Central and Eastern Europe Fund
CEE
$123M
| $8.94K | ﹤0.01% |
435
+109
| +33% | +$2.25K |
2014 Q4
46 quarters
|
|
8525
DELISTED
ProShares Smart Materials ETF
TINT
| $8.93K | ﹤0.01% |
224
+24
| +12% | +$962 |
2024 Q3
7 quarters
|
|
Similar funds
UBS Group's Q2 2026 Portfolio in Review
As of Q2 2026, UBS Group held 11,684 positions worth $786B, up 18% from $666B the previous quarter. Its ten largest holdings account for 13% of the portfolio.
UBS Group's Q2 2026 filing shows 1,282 new, 4,216 increased, 4,362 reduced and 1,275 closed positions. Its largest new stake was Honeywell Aerospace: 2,768,136 shares worth $612M. The largest sale was ExxonMobil, an estimated $1.49B.
By sector, the portfolio is most concentrated in Miscellaneous at 42% of assets, up from 39% a quarter earlier, followed by Technology and Financials.
- UBS Group's largest Q2 2026 buy was Honeywell Aerospace: 2,768,136 shares worth $612M.
- UBS Group added most to Microsoft in Q2 2026, an estimated $1.15B increase.
- UBS Group's biggest Q2 2026 reduction was ExxonMobil, cutting an estimated $1.49B.
- UBS Group fully exited Hologic in Q2 2026, selling an estimated $385M.
- UBS Group's ten largest holdings make up 13% of its $786B portfolio in Q2 2026.
- UBS Group opened 1,282 new positions and closed 1,275 in Q2 2026.
- UBS Group's portfolio value rose 18% quarter-over-quarter to $786B.
Based on UBS Group's 13F filing for Q2 2026, filed 13 Aug 2026.